ImClone Systems Incorporated (Nasdaq: IMCL), Merck KGaA, Darmstadt, Germany (Frankfurt Stock Exchange: MRK), and Bristol-Myers Squibb Company (NYSE: BMY) today announced the findings of two Merck KGaA-sponsored studies of ERBITUX(TM) (Cetuximab) Injection, an IgG1 monoclonal antibody, in patients with advanced squamous cell carcinoma of the head and neck (SCCHN), as presented at the American Society of Clinical Oncology (ASCO) 40th Annual Meeting. The studies assessed ERBITUX as a single agent in patients with platinum-refractory advanced SCCHN and in combination with platinum-based chemotherapy and 5-fluorouracil (5-FU) in patients with recurrent and/or metastatic SCCHN. The companies plan to discuss these study findings, as well as the previously announced results of a large international Phase III study also presented today (IMCL-9815), with the Food and Drug Administration (FDA) and the European Medicines Agency (EMEA).
